Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of rFIXFc in previously treated hemophilia B
NL-OMON40613Phase 3Active, not recruiting
- Sponsor
- Biogen
- Start
- Jan 2014
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of eftrenonacog alfa in hemophilia B (HB) (2 arms), sponsored by Biogen. Primary endpoint: Occurrence of inhibitor development. Started Jan 2014; status: active, not recruiting.
02
Drugs
eftrenonacog alfa
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NL-OMON40613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40613.